Anti-liver cancer NY-ESO-1b peptide vaccine approved for clinical trials
-
Last Update: 2020-07-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
at the recent annual meeting of theResearch Conference of the People'sHospital of Peking University, Chen Hongsong of the Institute of Hepatology of the Institute of Hepatology reported that after 9 years of pre-clinical research, thetumorantigen NY-ESO-1b peptide vaccine has finally been approved by the State Food and Drug Administration for Phase I clinical trialsChen Hongsong said thattumor-testicular (CT) antigen is currently identified as thetumorantigen sized the largest number of oneThe study found that the tumor antigen NY-ESO-1b peptide vaccine can successfully induce some Chinese liver cancer patients with special and significant immune response to anti-liver cancer, effectively kill the cancer cells left behind after surgery, reduce the metastasis and recurrence of liver cancer after surgery, may be an effective treatment for liver cancerIts Phase I clinical trial will recruit 20 patients in the near future(reproduced from the China Medical Tribune)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
